Bristlecone Advisors, LLC Athira Pharma, Inc. Transaction History
Bristlecone Advisors, LLC
- $1.24 Billion
- Q3 2024
A detailed history of Bristlecone Advisors, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Bristlecone Advisors, LLC holds 337,506 shares of ATHA stock, worth $195,753. This represents 0.01% of its overall portfolio holdings.
Number of Shares
337,506
Previous 85,306
295.64%
Holding current value
$195,753
Previous $226,000
33.19%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding ATHA
# of Institutions
66Shares Held
16.9MCall Options Held
112KPut Options Held
68K-
Perceptive Advisors LLC New York, NY5.4MShares$3.13 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.61MShares$935,5760.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$865,8190.39% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$865,8190.04% of portfolio
-
Black Rock Inc. New York, NY676KShares$392,2210.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $21.9M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...